Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency Aug 17, 2020
Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020 Aug 17, 2020
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Aug 14, 2020
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020 Aug 12, 2020
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Aug 10, 2020
Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Aug 10, 2020
Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Aug 05, 2020
Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease Jul 31, 2020
Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports Jul 29, 2020
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020 Jul 27, 2020
